Panion & Bf Biotech (TPE:1760) Beginning Cash Position: NT$460 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1760 Panion & Bf Biotech Inc TPE:1760
73 GF Score
Price NT$59.00
GF Value NT$91.30
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Panion & Bf Biotech Beginning Cash Position?

Panion & Bf Biotech TPE:1760 +0.34% 73 Beginning Cash Position is NT$460 Mil as of Mar. 2026. GuruFocus rates TPE:1760 with a GF Score™ of 73/100 and a GF Value™ of NT$91.30 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Panion & Bf Biotech's Beginning Cash Position for the quarter that ended in Mar. 2026 was NT$460 Mil.

Panion & Bf Biotech's quarterly Beginning Cash Position declined from Sep. 2025 (NT$522 Mil) to Dec. 2025 (NT$380 Mil) but then increased from Dec. 2025 (NT$380 Mil) to Mar. 2026 (NT$460 Mil).

Panion & Bf Biotech's annual Beginning Cash Position increased from Dec. 2023 (NT$464 Mil) to Dec. 2024 (NT$535 Mil) and increased from Dec. 2024 (NT$535 Mil) to Dec. 2025 (NT$558 Mil).

Panion & Bf Biotech Beginning Cash Position Related Terms

Panion & Bf Biotech Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Panion & Bf Biotech's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Panion & Bf Biotech Beginning Cash Position Chart

Panion & Bf Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 310.11 279.10 464.26 534.63 558.37

Panion & Bf Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 558.37 505.08 522.23 379.98 460.32
TPE:1760
73GF Score
Panion & Bf Biotech Inc TPE:1760
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Panion & Bf Biotech Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of NT$460 Mil mean?
Panion & Bf Biotech (TPE:1760) has a Beginning Cash Position of NT$460 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Panion & Bf Biotech and its competitors.
Is Panion & Bf Biotech's Beginning Cash Position too high?
Panion & Bf Biotech's current Beginning Cash Position is NT$460 Mil. Overall, Panion & Bf Biotech has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Panion & Bf Biotech's Beginning Cash Position compare to ZTS?
Panion & Bf Biotech's Beginning Cash Position of NT$460 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Panion & Bf Biotech and its competitors. Panion & Bf Biotech's current Beginning Cash Position is NT$460 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panion & Bf Biotech stock overvalued right now?
Based on GuruFocus' analysis, Panion & Bf Biotech (TPE:1760) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$91.30, compared to a current price of NT$59.00 — trading 35.4% below its estimated fair value. The current Beginning Cash Position is NT$460 Mil. Panion & Bf Biotech's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Panion & Bf Biotech (TPE:1760), the current Beginning Cash Position is NT$460 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Panion & Bf Biotech (TPE:1760) Overvalued in 2026?

Based on GuruFocus' analysis, Panion & Bf Biotech stock appears to be undervalued. The current stock price of NT$59.00 is trading 35.4% below its estimated GF Value™ of NT$91.30. GuruFocus considers Panion & Bf Biotech to be Significantly Undervalued.

Key valuation signals for TPE:1760:

  • Beginning Cash Position: NT$460 Mil
  • GF Value™: NT$91.30 vs. price of NT$59.00 (35.4% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the TPE:1760 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Panion & Bf Biotech Business Description

Address No. 3, Park Street, 16th Floor, Nangang District, Taipei, TWN, 11503
Panion & Bf Biotech Inc operates as a biotech and pharmaceutical company. The company, along with its subsidiaries, is mainly engaged in the manufacture and sales of pharmaceutical, cosmeceutical, diagnostic, medical device, and active pharmaceutical ingredients. It has four core business groups: disease treatment, disease prevention, disease diagnosis, and delayed aging. It has geographic segments in Taiwan; China, Hong Kong, and Macau; the USA; and Korea. It generates a majority of its revenue from the Taiwan segment. Product-wise the firm generates the majority of its revenue from Pharmaceutical products.
73GF Score

Get the complete analysis for TPE:1760

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$59.00
Price
NT$91.30
GF Value